MIDATECH PHARMA
R&D | HCC

Liver cancer is the third leading cause of cancer deaths worldwide, affecting approximately 500,000 people. Prognosis is poor since if the tumour cannot be surgically resected – as is the problem in up to 80% of cases - then patients usually do not survive beyond 6 months.  Midatech GNP’s are being developed to repurpose and improve existing therapies for liver cancer. By attaching targeting motifs together with chemotherapeutics on the same GNP, it is possible to alter the biodistribution of toxic chemotherapeutics to focus on the tumour and spare normal tissues. This shift in biodistribution can significantly improve the therapeutic index of treatments for this devastating disease.
 

Midatech Pharma has selected its wholly-owned candidate compound, MTR104, to take into a formal IND-enabling programme during 2017, followed by human studies planned for 2018. 

R&D
R&D
HCC

Liver cancer is the third leading cause of cancer deaths worldwide, affecting approximately 500,000 people. Prognosis is poor since if the tumour cannot be surgically resected – as is the problem in up to 80% of cases - then patients usually do not survive beyond 6 months.  Midatech GNP’s are being developed to repurpose and improve existing therapies for liver cancer. By attaching targeting motifs together with chemotherapeutics on the same GNP, it is possible to alter the biodistribution of toxic chemotherapeutics to focus on the tumour and spare normal tissues. This shift in biodistribution can significantly improve the therapeutic index of treatments for this devastating disease.
 

Midatech Pharma has selected its wholly-owned candidate compound, MTR104, to take into a formal IND-enabling programme during 2017, followed by human studies planned for 2018. 

© Copyright 2017 Midatech Pharma PLC